Skip to content

ALDEYRA THERAPEUTICS, INC.

ALDX

CIK 0001341235

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$30.84M
+39.4% YoY Q1 May 2026
EPS Diluted (TTM)
−$0.52
+40.4% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$37.03M
Q1 May 2026
Cash
$70.04M
Q1 May 2026
Total Debt
$15.3M
Q1 May 2026
Shares Outstanding
60.32M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings